Literature DB >> 6641723

Cross-reacting opsonic antibodies to clinically important pneumococcal serotypes after pneumococcal vaccination.

J H Braconier, E B Myhre, H Odeberg.   

Abstract

Opsonic activity of serum to pneumococcal serotypes 6 B, 9 V and 19 A was measured in 16 patients before and after immunization with a pneumococcal vaccine. The capsular polysaccharides of these serotypes are not included among, but are antigenically related to the vaccine polysaccharides. Patients responding to immunization with a twofold increase in serum antibodies to vaccine polysaccharides 6 A, 19 F and 23 F were studied. Increased opsonic activity towards serotypes 6 B, 9 V and 19 A was found in 12, four and ten patients respectively. In ten of the patients antibodies to serotypes 6 B, 9 V and 19 A were measured by a staphylococcal protein-A binding assay. A twofold increase in antibodies was found in postvaccination samples from ten, three and seven patients respectively. These results indicate that humans responding to pneumococcal vaccination, may also develop opsonic antibodies to other clinically important pneumococcal serotypes. The degree of cross-immunization appears to vary between individuals and between different pneumococcal serotypes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6641723     DOI: 10.1007/BF02013903

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  19 in total

1.  Prevention of pneumococcal pneumonia by vaccination.

Authors:  R Austrian; R M Douglas; G Schiffman; A M Coetzee; H J Koornhof; S Hayden-Smith; R D Reid
Journal:  Trans Assoc Am Physicians       Date:  1976

2.  Granulocyte function in chronic granulocytic leukaemia. I. Bactericidal and metabolic capabilities during phagocytosis in isolated granulocytes.

Authors:  H Odeberg; T Olofsson; I Olsson
Journal:  Br J Haematol       Date:  1975-03       Impact factor: 6.998

Review 3.  From the center for disease control. Epidemiology of pneumococcal serotypes in the United States, 1978--1979.

Authors:  C V Broome; R R Facklam; J R Allen; D W Fraser; R Austrian
Journal:  J Infect Dis       Date:  1980-01       Impact factor: 5.226

4.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

5.  Opsonic and antibody responses to pneumococcal polysaccharide types 6A, 19F and 23F after vaccination of immunocompromised patients.

Authors:  J H Braconier; F K Pedersen; H Odeberg; C Rosén
Journal:  Scand J Infect Dis       Date:  1984

6.  Cross-immunogenicity of pneumococcal group 9 capsular polysaccharides in adult volunteers.

Authors:  S C Szu; C J Lee; J C Parke; G Schiffman; J Henrichsen; R Austrian; S C Rastogi; J B Robbins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

7.  Comparative immunogenicity of group 6 pneumococcal type 6A(6) and type 6B(26) capsular polysaccharides.

Authors:  J B Robbins; C J Lee; S C Rastogi; G Schiffman; J Henrichsen
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

8.  Immunochemical characterization of cross-reactivity of pneumococcal group 9 capsular polysaccharide types 9N, 9A, 9L, and 9V.

Authors:  S Szu; C J Lee; D Carlo; J Henrichsen
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

9.  Streptococcus pneumoniae resistant to penicillin and chloramphenicol.

Authors:  P C Appelbaum; A Bhamjee; J N Scragg; A F Hallett; A J Bowen; R C Cooper
Journal:  Lancet       Date:  1977-11-12       Impact factor: 79.321

Review 10.  Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention.

Authors:  R Austrian
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr
View more
  1 in total

Review 1.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.